When synovial sarcoma spreads beyond its original location, the treatment approach shifts from local control to managing disease throughout the body. This challenging situation requires a combination of therapies aimed at slowing cancer progression, reducing symptoms, and maintaining quality of life for as long as possible.

Fighting a Rare and Aggressive Cancer: What Treatment Can Offer

Metastatic synovial sarcoma presents significant treatment challenges because this rare cancer has already traveled beyond the site where it first appeared. When the disease reaches this advanced stage, the goals of treatment change. Instead of aiming to cure the cancer completely, doctors focus on controlling its growth, managing uncomfortable symptoms, and helping patients maintain their ability to do the things they value in daily life. The treatment plan depends heavily on where the cancer has spread, how quickly it is growing, the patient’s overall health and age, and whether previous treatments have been tried.^[1]

Understanding that treatment is available and that research continues to explore new options can provide hope during a difficult time. Medical teams today have access to several established therapies that have shown benefit in slowing disease progression, and scientists are actively testing innovative approaches in clinical trials. The path forward involves working closely with specialists who understand this rare disease and can tailor treatment to each person’s unique situation.^[2]

Synovial sarcoma most commonly spreads to the lungs, though it can also reach lymph nodes and, less frequently, other soft tissues or bones. When cancer has metastasized, surgery alone is rarely sufficient, and doctors turn to treatments that can reach cancer cells throughout the entire body. These are called systemic treatments, meaning they work through the bloodstream to target cancer wherever it may be hiding.^[4]

Standard Treatment Approaches for Metastatic Disease

When synovial sarcoma has spread, the backbone of treatment is chemotherapy—medications designed to kill rapidly dividing cancer cells. Unlike radiation or surgery, which target specific areas, chemotherapy circulates through the bloodstream and can reach cancer cells in multiple locations at once. This makes it particularly valuable when dealing with metastatic disease.^[9]

The most commonly used chemotherapy drug for metastatic soft tissue sarcomas, including synovial sarcoma, is doxorubicin, which belongs to a family of drugs called anthracyclines. Doxorubicin works by interfering with the DNA inside cancer cells, preventing them from multiplying. Doctors typically administer doxorubicin through an intravenous infusion, often at a dose of 75 milligrams per square meter of body surface area, given as a continuous infusion over three days. This approach helps reduce some of the harsh side effects while maintaining the drug’s cancer-fighting power.^[9]

For patients who are otherwise healthy and able to tolerate more intensive treatment, doctors may combine doxorubicin with another powerful chemotherapy agent called ifosfamide. Ifosfamide is an alkylating agent, meaning it damages cancer cell DNA in a different way than doxorubicin. When used together, these two drugs attack cancer cells through multiple mechanisms, which can lead to better tumor shrinkage. Research suggests that this combination may improve outcomes for certain patients with metastatic disease, though it also brings more side effects than using doxorubicin alone.^[10]

The typical ifosfamide regimen involves giving 2.5 grams per square meter of body surface area daily for four consecutive days, alongside doxorubicin. Because ifosfamide can be toxic to the bladder and bone marrow, patients also receive supportive medications. One such medication is mesna, which protects the bladder from damage, and another is granulocyte colony-stimulating factor (G-CSF), which helps the bone marrow recover and produce white blood cells needed to fight infections.^[9]

Studies have shown that synovial sarcoma tends to be relatively more responsive to chemotherapy compared to some other types of soft tissue sarcoma. This means that a reasonable proportion of patients will see their tumors shrink or stop growing for a period of time when treated with these drugs. However, the response is often temporary, and the cancer may eventually find ways to resist the treatment.^[10]

When First-Line Treatment Stops Working

If doxorubicin-based chemotherapy fails to control the cancer, or if the disease progresses after an initial response, doctors turn to second-line treatments. One option is pazopanib, an oral medication that belongs to a class called tyrosine kinase inhibitors. Pazopanib works by blocking signals that cancer cells use to build new blood vessels—a process called angiogenesis. Without these blood vessels, tumors struggle to get the oxygen and nutrients they need to grow. Clinical trials have demonstrated that pazopanib can slow disease progression in patients with advanced soft tissue sarcomas, including synovial sarcoma.^[10]

Another second-line option is trabectedin, a chemotherapy drug derived originally from a sea creature. Trabectedin has a unique mechanism: it binds to the DNA in cancer cells and disrupts their ability to repair damage and replicate. This drug has shown activity in various soft tissue sarcomas and is typically given as an intravenous infusion once every three weeks.^[10]

For some patients, particularly those with specific tumor characteristics, other chemotherapy regimens may be considered. These can include combinations like docetaxel with gemcitabine, or single agents such as eribulin or dacarbazine. Dacarbazine has shown some promise in certain sarcoma types, including leiomyosarcoma and solitary fibrous tumors, though its role in synovial sarcoma specifically is less well defined.^[9]

Duration and Side Effects of Chemotherapy

How long a patient continues chemotherapy depends on how well the cancer responds and how well the person tolerates the treatment. If scans show that tumors are shrinking or remaining stable, and if side effects are manageable, treatment may continue for several months or even longer. However, if the cancer continues to grow despite therapy, or if side effects become too severe, doctors will discuss stopping the current treatment and considering alternatives.^[10]

Chemotherapy can cause significant side effects because these drugs affect not just cancer cells but also healthy cells that divide rapidly, such as those in the bone marrow, digestive tract, and hair follicles. Common side effects of doxorubicin include fatigue, nausea, vomiting, hair loss, mouth sores, and an increased risk of infection due to low white blood cell counts. Doxorubicin can also affect the heart over time, so doctors monitor heart function carefully, especially if patients receive high cumulative doses.^[9]

Ifosfamide can cause confusion, bladder irritation (which is why mesna is given alongside it), and suppression of bone marrow function, leading to low blood counts. Patients on this regimen need close monitoring with regular blood tests to ensure their body can handle the treatment.^[9]

Pazopanib, being a targeted therapy rather than traditional chemotherapy, has a different side effect profile. Common issues include high blood pressure, fatigue, diarrhea, nausea, hair color changes, and liver enzyme abnormalities. Because it’s taken as a pill at home, patients need regular clinic visits to monitor blood pressure and liver function.^[10]

The Role of Surgery and Radiation in Metastatic Disease

Even when cancer has spread, surgery can still play a role in selected cases. If metastases are limited to a few spots in the lungs and can be safely removed, some patients may benefit from surgical resection of these lesions. This approach, sometimes called metastasectomy, is most effective when the primary tumor has been controlled and there are only a small number of lung nodules. While it doesn’t cure the disease, removing visible tumors can sometimes extend survival and improve quality of life.^[7]

Similarly, radiation therapy may be used to treat specific areas where the cancer is causing problems, such as painful bone metastases or tumors pressing on nerves or vital structures. This is called palliative radiation, meaning its goal is to relieve symptoms rather than cure the cancer. Radiation can be very effective at shrinking tumors in specific spots and providing relief from pain or other symptoms.^[12]

Innovative Treatments Being Explored in Clinical Trials

Because metastatic synovial sarcoma remains difficult to treat with standard therapies alone, researchers are actively investigating new approaches. Clinical trials offer patients access to cutting-edge treatments that may not yet be widely available. Participating in a trial also contributes valuable information that can help future patients.^[1]

Immunotherapy: Teaching the Immune System to Fight Cancer

One of the most exciting areas of research involves harnessing the body’s own immune system to recognize and attack cancer cells. Synovial sarcoma cells carry a unique genetic abnormality—a fusion between the SS18 gene and one of several SSX genes on the X chromosome. This fusion creates proteins that are not found in normal cells, making them potential targets for the immune system.^[1]

A groundbreaking type of immunotherapy called adoptive cell therapy has shown promise in clinical trials. In this approach, doctors collect a patient’s own immune cells (specifically, T cells) from their blood. These T cells are then genetically modified in a laboratory to recognize the SS18-SSX fusion protein that synovial sarcoma cells display on their surface. Once the T cells have been “trained” to target the cancer, they are multiplied to create millions of copies and then infused back into the patient’s bloodstream. These engineered T cells can then seek out and destroy cancer cells wherever they hide in the body.^[6]

One such therapy, known commercially as afamitresgene autoleucel (also called TECELRA), received approval from the U.S. Food and Drug Administration based on clinical trial data showing that some patients with advanced synovial sarcoma experienced tumor shrinkage when other treatments had failed. The therapy specifically targets cells expressing the MAGE-A4 protein, which is commonly found on synovial sarcoma cells. In the clinical study that led to approval, patients received this therapy after having tried other standard treatments without success. While not everyone responded, those who did saw meaningful reductions in their tumor burden.^[6]

This type of treatment requires significant preparation and careful monitoring. Before receiving the engineered T cells, patients undergo a procedure called leukapheresis, where their blood is filtered to collect T cells. This process takes several hours but is generally well tolerated. The collected cells are then sent to a specialized facility where they are modified and expanded, which takes several weeks. During this time, patients may receive chemotherapy to prepare their body for the infusion of modified cells. After receiving the therapy, patients must be monitored closely, often staying near a specialized treatment center for at least a month, because the treatment can cause significant side effects.^[6]

Side effects of adoptive cell therapy can be serious and require immediate medical attention. One complication is cytokine release syndrome, which occurs when the infused T cells become very active and release large amounts of inflammatory molecules into the bloodstream. This can cause high fever, low blood pressure, difficulty breathing, and other symptoms that may require intensive care support. Another potential problem is damage to normal tissues if the engineered T cells mistakenly attack healthy cells. Despite these risks, for patients who have run out of other options, this therapy represents a potentially life-extending treatment.^[6]

Targeting the SS18-SSX Fusion and Related Pathways

Scientists are working to develop drugs that specifically target the abnormal SS18-SSX fusion protein itself or the cellular pathways it disrupts. The fusion protein interferes with a complex inside cells called the BAF complex, which normally helps regulate which genes are turned on or off. By disrupting this complex, the fusion protein causes cells to behave abnormally and become cancerous.^[1]

Researchers are testing compounds called epigenetic modulators that can influence how genes are expressed without changing the DNA sequence itself. Some of these drugs target enzymes called histone deacetylases (HDACs) or EZH2, which play roles in controlling gene activity. The idea is that by altering the epigenetic landscape of cancer cells, these drugs might be able to reverse some of the abnormal behavior caused by the SS18-SSX fusion. Several such agents are being evaluated in early-phase clinical trials for synovial sarcoma and other cancers.^[10]

Receptor Tyrosine Kinase Inhibitors

Beyond pazopanib, which is already approved, researchers are testing other drugs that block different receptor tyrosine kinases—proteins on the cell surface that send growth signals into the cell. By blocking these receptors, the drugs can slow cancer cell growth and cut off blood supply to tumors. Various kinase inhibitors are in clinical trials for advanced soft tissue sarcomas, including synovial sarcoma, to see if they might offer better results or fewer side effects than current options.^[10]

DNA Damage Response Inhibitors

Another strategy involves exploiting cancer cells’ weaknesses in repairing DNA damage. Drugs that inhibit DNA damage response pathways, such as PARP inhibitors or checkpoint kinase inhibitors, are being studied in combination with chemotherapy. The theory is that cancer cells already stressed by chemotherapy will be less able to repair the damage if these repair pathways are blocked, leading to cell death. These approaches are still experimental and are being tested in clinical trials.^[10]

Monoclonal Antibodies and Vaccine Approaches

Scientists have developed experimental monoclonal antibodies that target specific proteins found on synovial sarcoma cells. One such target is FZD10, a cell-surface receptor that is present on synovial sarcoma cells but not on most normal tissues. Early research in laboratory models showed that antibodies targeting FZD10 could attack synovial sarcoma cells without harming healthy organs. While this approach has not yet reached widespread clinical testing, it represents another potential avenue for future treatment.^[9]

Additionally, researchers are exploring peptide vaccines designed to train the immune system to recognize fragments of the SS18-SSX fusion protein. The idea is that by repeatedly exposing the immune system to these protein fragments, the body might develop a stronger and more sustained immune response against the cancer. These vaccine strategies are still in early research phases.^[9]

Understanding Clinical Trial Phases

When reading about clinical trials, it’s helpful to understand the different phases. Phase I trials are the first step in testing a new treatment in humans and focus primarily on determining what dose is safe and what side effects occur. These trials usually involve a small number of patients. Phase II trials test whether the treatment actually works against the cancer—do tumors shrink, and does the disease stop progressing? These trials enroll more patients and provide preliminary evidence of effectiveness. Phase III trials compare the new treatment directly against the current standard treatment to see if the new approach is better. These are large studies that often involve hundreds of patients across multiple centers.^[1]

Clinical trials for metastatic synovial sarcoma are conducted at specialized cancer centers around the world, including in the United States, Europe, and other regions. Eligibility for trials depends on many factors, such as the extent of disease, previous treatments received, overall health status, and specific characteristics of the tumor (like the presence of the SS18-SSX fusion or expression of certain proteins). Patients interested in clinical trials should discuss options with their oncology team, who can help identify appropriate studies and explain the potential benefits and risks.^[7]

Most common treatment methods

• Chemotherapy
  • Doxorubicin (anthracycline): typically given as 75 mg/m² via continuous infusion over three days, works by interfering with cancer cell DNA
  • Ifosfamide: used at 2.5 g/m² daily for four days, often combined with doxorubicin in fit patients, requires supportive medications like mesna and G-CSF
  • Combination of doxorubicin and ifosfamide: shown to improve tumor response rates in metastatic disease, though with increased side effects
  • Second-line options include docetaxel with gemcitabine, eribulin, or dacarbazine
  • Ifosfamide combined with etoposide is another regimen used in some cases
• Targeted therapy
  • Pazopanib: oral tyrosine kinase inhibitor that blocks angiogenesis, used in second-line treatment for patients who have progressed on chemotherapy
  • Trabectedin: unique chemotherapy derived from sea organisms, given as intravenous infusion every three weeks, shows activity in various soft tissue sarcomas
  • Other receptor tyrosine kinase inhibitors under investigation in clinical trials
• Immunotherapy
  • Afamitresgene autoleucel (TECELRA): genetically modified T cell therapy targeting MAGE-A4 protein on synovial sarcoma cells, approved based on clinical trial showing tumor shrinkage in some patients with advanced disease
  • Requires leukapheresis to collect T cells, laboratory modification of cells, and close monitoring after infusion
  • Experimental monoclonal antibodies targeting FZD10 receptor in preclinical studies
  • Peptide vaccines based on SS18-SSX fusion protein under early investigation
• Surgical therapy
  • Metastasectomy: surgical removal of limited lung metastases when technically feasible
  • Most effective when primary tumor is controlled and there are only a few accessible metastases
  • Goal is to extend survival and improve quality of life rather than cure
• Radiation therapy
  • Palliative radiation for symptomatic metastases causing pain or compressing vital structures
  • Can effectively shrink tumors in specific locations and provide symptom relief
  • Particularly useful for bone metastases or lesions near nerves
• Experimental approaches in clinical trials
  • Epigenetic modulators targeting histone deacetylases (HDACs) or EZH2 to reverse abnormal gene expression caused by SS18-SSX fusion
  • DNA damage response inhibitors such as PARP inhibitors or checkpoint kinase inhibitors, often combined with chemotherapy
  • Novel kinase inhibitors targeting different growth signaling pathways
  • Combination strategies testing multiple targeted agents together